Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly(ADP-ribose) polymerase family member 15 (PARP15)
- Target
- PARP15
- Molecular classification
- Enzyme, Mono(ADP-ribosyl) transferase, Poly(ADP-ribose) polymerase family
01
Overview
Poly(ADP-ribose) polymerase family member 15 (PARP15) is an enzyme belonging to the PARP family, which are characterized by their ability to catalyze the transfer of ADP-ribose units from NAD+ onto target proteins. PARP15 specifically catalyzes mono(ADP-ribosyl)ation rather than the formation of poly(ADP-ribose) chains, and shows weak automodification ability, instead favoring modification of other proteins. PARP family members play important roles in DNA repair, genomic stability, stress responses, and cell signaling, but the unique biological and disease functions of PARP15 are less thoroughly characterized than major PARPs like PARP1/2. As of current knowledge, PARP15 is not the primary therapeutic target of any approved drugs, but may be implicated in broader pathways relevant to cancer and cell stress.
- Other names
- PARP-15Poly(ADP-ribose) polymerase 15
02
Mechanism of action
Mono(ADP-ribosyl)ation of target proteins using NAD+ as substrate Likely influences cellular function through regulation of protein interactions and stability within stress responses
03
Biological functions
Post-translational protein modification (mono-ADP-ribosylation)Cellular stress responsePotential involvement in signal transduction and chromatin regulation (by analogy with other PARPs)
04
Disease associations
Cancer (implicated in some studies through the broader PARP family's roles)Other (direct disease links for PARP15 specific remain minimal but are possible through its enzyme family)
05
Safety considerations
No safety concerns specific to PARP15 currently documented; for PARP family, off-target effects or disruptions to DNA repair or energy metabolism are general considerations
06
Interacting drugs
None specifically established for PARP15 as of current evidence; drugs such as PARP inhibitors (e.g., olaparib, talazoparib) target other PARP family members
1 more in the full profile.
07
Biomarkers
None specific for PARP15 currently validated; PARP activity in general can be a biomarker in oncology (e.g., for other PARP family members in cancer therapy)
Beyond the preview
Go deeper on Poly(ADP-ribose) polymerase family member 15 (PARP15).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poly(ADP-ribose) polymerase family member 15 (PARP15).